We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+16.95%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$1.52B
AUM Growth
-$7.28B
Cap. Flow
-$6.76B
Cap. Flow %
-444.29%
Top 10 Hldgs %
100%
Holding
929
New
Increased
6
Reduced
3
Closed
920

Sector Composition

Rank Sector Weight
1 Technology 45.54%
2 Healthcare 36.97%
3 Financials 14.43%
4 Communication Services 3.06%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BIOS
576
DELISTED
BioPlus Acquisition Corp. Class A Ordinary Shares
BIOS
-467,907
Closed -$4.7M
BIOSW
577
DELISTED
BioPlus Acquisition Corp. Warrants
BIOSW
-187,997
Closed -$27K
FZT
578
DELISTED
FAST Acquisition Corp. II
FZT
-391,575
Closed -$3.84M
LFAC
579
DELISTED
LF Capital Acquisition Corp. II Class A Common Stock
LFAC
-477,246
Closed -$4.8M
MPRA
580
DELISTED
Mercato Partners Acquisition Corporation Class A Common Stock
MPRA
-381,797
Closed -$3.82M
ICNC
581
DELISTED
Iconic Sports Acquisition Corp.
ICNC
-477,246
Closed -$4.85M
GFGD
582
DELISTED
The Growth for Good Acquisition Corporation Class A Ordinary Shares
GFGD
-467,907
Closed -$4.61M
ADER
583
DELISTED
26 Capital Acquisition Corp
ADER
-272,208
Closed -$2.69M
DBTX
584
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
-157,745
Closed -$546K
MBSC
585
DELISTED
M3-Brigade Acquisition III Corp.
MBSC
-381,797
Closed -$3.85M
UTAA
586
DELISTED
UTA Acquisition Corporation Class A Ordinary Shares
UTAA
-514,697
Closed -$5.16M
PIAI
587
DELISTED
Prime Impact Acquisition I
PIAI
-471,326
Closed -$4.74M
NSTD
588
DELISTED
Northern Star Investment Corp. IV
NSTD
-142,709
Closed -$1.4M
ATAQ
589
DELISTED
Altimar Acquisition Corp III
ATAQ
-380,556
Closed -$3.77M
NSTC
590
DELISTED
Northern Star Investment Corp. III
NSTC
-144,714
Closed -$1.43M
FGMC
591
DELISTED
FG Merger Corp. Common Stock
FGMC
-229,785
Closed -$2.3M
FWAC
592
DELISTED
Fifth Wall Acquisition Corp. III Class A Ordinary Shares
FWAC
-939,550
Closed -$9.24M
GFX
593
DELISTED
Golden Falcon Acquisition Corp.
GFX
-195,521
Closed -$1.95M
FORG
594
DELISTED
ForgeRock, Inc.
FORG
-28,199
Closed -$410K
ZING
595
DELISTED
FTAC Zeus Acquisition Corp. Class A Common Stock
ZING
-949,823
Closed -$9.55M
APMI
596
DELISTED
AxonPrime Infrastructure Acquisition Corporation Class A Common Stock
APMI
-238,623
Closed -$2.31M
AFTR
597
DELISTED
AfterNext HealthTech Acquisition Corp
AFTR
-1,441,079
Closed -$14.1M
CPAA
598
DELISTED
Conyers Park III Acquisition Corp. Class A Common Stock
CPAA
-2,961,691
Closed -$28.8M
CPAAW
599
DELISTED
Conyers Park III Acquisition Corp. Warrants
CPAAW
-1,012,165
Closed -$257K
ARBGW
600
DELISTED
Aequi Acquisition Corp warrants
ARBGW
-158,411
Closed -$6K

Similar funds

UBS O'Connor's Q4 2022 Portfolio in Review

As of Q4 2022, UBS O'Connor held 929 positions worth $1.52B, down 83% from $8.8B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

UBS O'Connor withdrew a net $6.76B in Q4 2022, closing 920 positions and reducing 3 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $572M position sold in full.

By sector, the portfolio is most concentrated in Technology at 46% of assets, up from 28% a quarter earlier, followed by Healthcare and Financials.

Against the trend, UBS O'Connor added an estimated $184M to Horizon Therapeutics Public Limited Company Ordinary Shares.

  • UBS O'Connor added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022, an estimated $184M increase.
  • UBS O'Connor's biggest Q4 2022 reduction was Activision Blizzard, cutting an estimated $45.3M.
  • UBS O'Connor fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $572M.
  • UBS O'Connor's ten largest holdings make up 100% of its $1.52B portfolio in Q4 2022.
  • UBS O'Connor opened 0 new positions and closed 920 in Q4 2022.
  • UBS O'Connor's portfolio value fell 83% quarter-over-quarter to $1.52B.

Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.